Transanal versus Laparoscopic Total Mesorectal Excision in Male Patients with Low Tumor Location after Neoadjuvant Therapy: A Propensity Score-Matched Cohort Study

Table 1

Demographic and clinical data before and after propensity score matching.

Characteristics	Before propensity score matching			After propensity score matching
	taTME ()	laTME ()		taTME ()	laTME ()
Age, (range)	(23-78)	(20-80)	0.08	(23-78)	(26-79)	0.80
BMI, (range)	(17.1-37.6)	(15.9-34.2)	0.10	(17.2-32.3)	(16.9-34.3)	0.85
Tumor location, (range)	(1.0-5.0)	(1.4-5.0)	<0.001	(2.0-5.0)	(1.4-5.0)	0.20
Tumor size (cm), (range)	(0.3-6.6)	(0-8.0)	0.07	(0.3-6.6)	(0-8.0)	0.20
Preoperative intestinal obstruction, (%)			<0.001			—
None	112 (100%)	199 (93.4%)		106 (100%)	106 (100%)
Incomplete	0 (0%)	14 (6.6%)		—	—
History of past abdominal surgery, (%)			0.68			1.00
Without	105 (93.8%)	202 (94.8%)		101 (95.3%)	102 (96.2%)
With	7 (6.3%)	11 (5.2%)		5 (4.7%)	4 (3.8%)
cT, (%)			0.23			0.53
T0	0 (0%)	1 (0.5%)		—	—
T1	1 (0.9%)	1 (0.5%)		1 (0.9%)	0 (0%)
T2	12 (10.7%)	41 (19.2%)		12 (11.3%)	18 (17.0%)
T3	90 (80.4%)	156 (73.2%)		86 (81.1%)	82 (77.4%)
T4	9 (8%)	14 (6.6%)		7 (6.6%)	6 (5.7%)
cN, (%)			0.09			0.63
N0	63 (56.3%)	145 (68.1%)		60 (56.6%)	66 (62.3%)
N1	33 (29.5%)	47 (22.1%)		31 (29.2%)	25 (23.6%)
N2	16 (14.3%)	21 (9.9%)		15 (14.2%)	15 (14.2%)
cM, (%)			0.24			1.00
M0	108 (96.4%)	210 (98.6%)		102 (96.2%)	103 (97.2%)
M1	4 (3.6%)	3 (1.4%)		4 (3.8%)	3 (2.8%)
Type of neoadjuvant therapy regimen, (%)			<0.001			0.47
Only chemotherapy	77 (68.8%)	89 (41.8%)		71 (67.0%)	66 (62.3%)
Radiochemotheraoy	35 (31.3%)	121 (56.8%)		35 (33.0%)	40 (37.7%)
Only radiotherapy	0(0%)	3(1.4%)		—	—